[Translation] A multicenter, randomized, double-blind, placebo-controlled phase II clinical trial of Qihong capsule in the treatment of chronic heart failure (Qi deficiency and blood stasis syndrome)

探索芪红胶囊治疗慢性心力衰竭（气虚血瘀证）的有效性与安全性，为 III 期临床研究提供依据。

[Translation]

To explore the effectiveness and safety of Qihong Capsule in the treatment of chronic heart failure (Qi deficiency and blood stasis syndrome) and provide a basis for Phase III clinical research.

Start Date16 Aug 2021

Sponsor / Collaborator

Xinjiang Uygur Autonomous Region Chinese Medicine Hospital

100 Clinical Results associated with Qihong Capsule

100 Translational Medicine associated with Qihong Capsule

100 Patents (Medical) associated with Qihong Capsule

Literatures (Medical) associated with Qihong Capsule

01 Jun 2010·Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

[Effect of Qihong capsule on HeLa cells infected by coxsackievirus B3 in vitro].

Article

Author: Liu, Zhe ; Song, Xiao-Dong ; Hui, Ru-Tai ; Sun, Kai ; Chen, Jing-Zhou

OBJECTIVETo investigate the effects of Qihong capsule (QH) on HeLa cells infected by coxsackievirus B3 (CVB3) in vitro and its potential antiviral mechanism.METHODSHeLa cells were infected by CVB3 in vitro. XTT assay and plaque inhibition assay were performed to determine the 50 % effective dose, (ED50), 50 % inhibitory concentration (IC50), and 50% cytotoxicity concentration (CC50) of QH and the control drug, ribavirin. The total therapeutic index (TI) was calculated. Anti-viral time-course experiments were performed to compare the anti-viral effects at different time points. The inhibitory effects of QH on the attachment and penetration of CVB3 were also observed.RESULTSXTT assay and plaque inhibition assay showed that the ED50 and IC50 were (7.16+/-0.80) mg/L and (2.63+/-0.50) mg/L in QH group and (4.35+/-0.40) mg/L and (1.92+/-0.30) mg/L in ribavirin group, respectively. CC50 was 16-fold higher in QH group than in ribavirin group QH: (1 648+/-219) mg/L vs. Ribavirin: (103+/-14) mg/L. Time-course studies demonstrated that antiviral effect of QH was mainly found 0-4 hours after infection. QH effectively blocked the attachment and penetration of CVB3 into cells.CONCLUSIONBy inhibiting the attachment and penetration of CVB3, QH can effectively inhibit the invasion of virus in vitro with low toxicity.

01 Jun 2005·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Effect of qihong capsule in inhibiting cell apoptosis induced by Coxsackie virus B].

Article

Author: Wang, Lun ; Song, Xiao-dong ; Ji, Bo

OBJECTIVETo investigate whether the cell apoptosis could be induced by Coxsackie virus B (Cox B) and Qihong capsule (QHC) has the inhibition on the cell apoptosis.METHODSCultured cells were divided into 4 groups, the Cox B infected group, the QHC treated and the Cox B infected group, the QHC control group and the normal control group. The cells apoptosis was determined by TUNEL labeled in situ, Hoechst 33258 staining and Annexin-V/PI staining, the apoptotic incidence was assayed by flow cytometry, and the change in expression of apoptotic related cytokines was measured with RT-PCR.RESULTSThe Cox B infected cell nucleus displayed strong blue fluorescence by Hoechst 33258 staining, and typical change of apoptotic cells could be detected. HeLa cell membrane showed strong green fluorescence and nucleus showed strong red fluorescence by Annexin-V/PI staining. Flow cytometric observation on DNA of PI stained cells showed obviously an apoptotic peak in the Cox B infected group. QHC could decrease the apoptosis incidence, while there was no cell apoptosis occurred in the normal control group. Besides, QHC could regulate the expression of apoptotic related cytokines.CONCLUSIONQHC has effect in inhibiting cell apoptosis induced by Cox B.

100 Deals associated with Qihong Capsule

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic heart failure	Phase 2	China	Xinjiang Uygur Autonomous Region Chinese Medicine Hospital	16 Aug 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Qihong Capsule

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation